SCHEMBL3877310

SCHEMBL3877310

Cc1cccnc1N1CCN(c2cc(-c3cccc(OC(C)C)c3)nc(N3CCOCC3)n2)[C@H](C)C1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 10/20 0.42
KDM4E B2RXH2 1/20 0.42
ALDH1A1 P00352 1/20 0.42
LMNA P02545 1/20 0.42
GAA P10253 1/20 0.42
HPGD P15428 1/20 0.42
HTT P42858 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C9 P11712 1/20 0.42
TSHR P16473 1/20 0.42
MAPK1 P28482 1/20 0.42
CYP2C19 P33261 1/20 0.42
HSD17B10 Q99714 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
ACACB O00763 1/20 0.41
TRPV1 Q8NER1 2/20 0.39
MTOR P42345 3/20 0.38
PIK3CB P42338 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3884783 0.92 TRPV1 (0.43) PIK3CAKDM4EALDH1A1LMNAGAA
SCHEMBL3879034 0.91 CYP1A2 (0.51) PIK3CAKDM4EHPGDCYP1A2CYP3A4
SCHEMBL3878696 0.90 ACACB (0.43) PIK3CAKDM4EALDH1A1GAAHPGD
SCHEMBL3876620 0.88 CYP1A2 (0.47) PIK3CAKDM4EHPGDNPSR1CYP1A2
SCHEMBL3888123 0.88 PIK3CA (0.43) PIK3CAKDM4ELMNAHPGDCYP1A2
SCHEMBL3883895 0.86 PIK3CA (0.45) PIK3CAKDM4EALDH1A1LMNAHPGD
SCHEMBL3884732 0.85 TRPV1 (0.42) PIK3CAKDM4ELMNAHPGDTSHR
SCHEMBL3879904 0.85 TRPV1 (0.43) PIK3CAKDM4ELMNAGAAHPGD
SCHEMBL3888346 0.85 PIK3CA (0.43) PIK3CAKDM4ELMNAHPGDCYP1A2
SCHEMBL3878058 0.85 PIK3CA (0.43) PIK3CAACACBTRPV1MTORPIK3CB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7566712-B2 Biaryl piperazinyl-pyridine analogues NEUROGEN CORPORATION (US) 2009-07-28 US disclosed
US-7566712-B2 Biaryl piperazinyl-pyridine analogues NEUROGEN CORPORATION (US) 2009-07-28 US disclosed
US-20070027155-A1 Biaryl piperazinyl-pyridine analogues NEUROGEN CORPORATION 2007-02-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070027155-A1 Biaryl piperazinyl-pyridine analogues GPR174, GPR68, PPARG PIK3CA 1107/4885KDM4E 3890/4885ALDH1A1 920/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.